N-(2-氧代乙基)氨基甲酸苄酯 | 67561-03-9

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-氧代乙基)氨基甲酸苄酯
• 英文名称: N-benzyloxycarbonylglycinal
• 英文别名: benzyl (2-oxoethyl)carbamate；benzyl N-(2-oxoethyl)carbamate
• CAS: 67561-03-9
• 化学式: C₁₀H₁₁NO₃
• 分子量: 193.202
• InChiKey: QSNONXQMKXTNQH-UHFFFAOYSA-N

物化性质

• 沸点：
  342.5±35.0 °C(Predicted)
• 密度：
  1.171±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

制备方法与用途

N-(2-氧代乙基)氨基甲酸苄酯可用作有机合成中间体和医药中间体，在实验室研发和化工生产过程中发挥重要作用。

反应信息

• 作为反应物：
  描述：

  N-(2-氧代乙基)氨基甲酸苄酯 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 甲醇 、 1,2-二氯乙烷 为溶剂， 反应 1.0h， 生成 benzyl N-[2-[[(3aR,4R,6R,6aR)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl-propan-2-ylamino]ethyl]carbamate
  参考文献：
  名称：

  [EN] MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF
  [FR] MODULATEURS D'HISTONE MÉTHYLTRANSFÉRASE ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  公开号：

  WO2012082436A3
• 作为产物：
  描述：

  benzyl chlorocarbamate 在 chromium dichloride 、 溶剂黄146 作用下， 生成 N-(2-氧代乙基)氨基甲酸苄酯
  参考文献：
  名称：

  The chromous chloride promoted addition of N-chlorocarbamates to enol ethers the synthesis of N-alkoxycarbonyl derivatives of 2-amino sugars and of α-amino ketones and aldehydes

  摘要：

  DOI：

  10.1016/s0040-4039(00)99735-1

文献信息

• [EN] FUSED QUINOLINE DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ DE QUINOLINE FUSIONNÉE ET UTILISATION DE CELUI-CI
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005105802A1

  公开（公告）日：2005-11-10

  The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein Rl is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6 is (cyclic group optionally having substituent(s)) -carbonyl, and the like; R7, R8, R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and --- represents a single bond or a double bond, or a salt thereof, and the like.

  本发明旨在提供一种具有神经激肽2（NK2）受体拮抗作用的喹啉衍生物，并涉及一种由式（I）表示的化合物，其中R1是氢原子等；R2是氢原子，可选地具有取代基的碳氢基团等；R3是未取代的（即缺失），氢原子等；R4和R5相同或不同，每个是氢原子，可选地具有取代基的碳氢基团等；R6是（环状基团，可选地具有取代基）-羰基等；R7、R8、R9和R10相同或不同，每个是氢原子，卤素等；或R7和R8、R8和R9、以及R9和R10可以与相邻的碳原子一起形成环；n是1到5的整数；---表示未取代的（即缺失）或单键；---表示单键或双键，或其盐等。
• Macrocyclic MCL-1 inhibitors and methods of use
  申请人：AbbVie Inc.

  公开号：US20190055264A1

  公开（公告）日：2019-02-21

  The present disclosure provides for compounds of Formula (I) wherein A 2 , A 3 , A 4 , A 6 , A 7 , A 8 , A 15 , R A , R 5 , R 9 , R 10A , R 10B , R 11 , R 12 , R 13 , R 14 , R 16 , W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

  本公开提供了Formula (I)的化合物，其中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y具有规范中定义的任何值，以及其药学上可接受的盐，可用作治疗疾病和病况的药物，包括癌症。还提供了包含Formula (I)化合物的药物组合物。
• Two-way homologation of aliphatic aldehydes: Both one-carbon shortening and lengthening via the same intermediate
  作者：Jae Won Yoo、Youngran Seo、Jong Beom Park、Young Gyu Kim

  DOI：10.1016/j.tet.2019.130883

  日期：2020.2

  Aliphatic aldehydes can be homologated to both one-carbon shorter and one-carbon longer homologous carbonyl compounds through the 2–4 steps of reactions via the same intermediates, β,γ-unsaturated α-nitrosulfones, prepared from the proline-catalyzed sequential reactions of several aliphatic aldehydes with phenylsulfonylnitromethane. While the oxidative cleavage of the key intermediates gave one-carbon

  脂肪醛可通过相同的中间体β，γ-不饱和α-硝基砜，经脯氨酸催化的连续反应制备的相同中间体，通过2–4个反应，与一碳短和一碳长的同源羰基化合物同源。几种脂肪醛与苯磺酰基硝基甲烷。当关键中间体的氧化裂解得到一碳较少的同源羰基化合物时，相同关键中间体的还原随后被氧化产生了更多一碳的同源羰基化合物。
• A catalyst-free, efficient green MCR protocol for access to functionalized γ-carbolines in water
  作者：Anuradha Dagar、Soumen Biswas、Sampak Samanta

  DOI：10.1039/c5ra08422a

  日期：——

  functionalized γ-carboline derivatives has been successfully realized in water through a one-pot three-component reaction involving several aryl/hetero-aryl/alkyl/alkenyl/alkynyl/ferrocenyl aldehydes, 3-formyl indole derivatives and ammonium acetate as a cheap N-source. The most important feature of the current methodology is that this hetero-annulation reaction of indole to γ-carboline can occur in good

  通过涉及几个芳基/杂芳基/烷基/烯基/炔基/二茂铁基醛的一锅三组分反应，已经成功地在水中实现了构建官能化γ-咔啉衍生物的通用，温和，有效和实用的方法， 3-甲酰基吲哚衍生物和乙酸铵作为廉价的N源。当前方法学的最重要特征是，从室温下无催化剂和氧化剂的廉价廉价原料开始，吲哚与γ-咔啉的杂环化反应可以在室温下以较宽的底物范围以良好至极好的收率发生。无条件。此外，通过我们的方法，已经可以轻松获得五环喹啉酮稠合的咔啉衍生物。
• NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
  申请人：CHO Young Lag

  公开号：US20120264727A1

  公开（公告）日：2012-10-18

  The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R 1 , and R 2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

  本发明涉及由化学公式1表示的新型头孢菌素衍生物。其中，X、Y、L、R1和R2与发明描述中定义的相同。本发明还涉及包含由化学公式1表示的新型头孢菌素衍生物、前药、水合物、溶剂化物、异构体或药用可接受盐作为有效成分的药物抗生素组合物。根据本发明，新型头孢菌素衍生物、前药、水合物、溶剂化物、异构体或药用可接受盐作为广谱抗生素耐药、低毒性的有效成分，特别是在革兰氏阴性细菌中，可以具有强大的抗菌活性。